Valneva (NASDAQ:VALN) Shares Gap Up – What’s Next?

Valneva SE Sponsored ADR (NASDAQ:VALN) shares gapped up before the market opened on Monday . The stock had previously closed at $5.05, but opened at $5.28. Valneva shares last traded at $5.2410, with a volume of 7,045 shares traded.

Analyst Ratings Changes

VALN has been the topic of a number of recent research reports. Guggenheim set a $11.00 target price on shares of Valneva in a report on Thursday, April 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valneva in a research report on Thursday, June 18th. The Goldman Sachs Group downgraded Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target on the stock. in a report on Wednesday, April 22nd. Finally, Wall Street Zen upgraded Valneva from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st. Three investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, Valneva presently has a consensus rating of “Hold” and an average price target of $11.97.

Valneva Stock Performance

The firm has a market cap of $502.90 million, a price-to-earnings ratio of -2.83 and a beta of 1.77. The stock’s fifty day moving average is $5.55 and its two-hundred day moving average is $7.64. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.60 and a current ratio of 2.14.

Valneva (NASDAQ:VALN) last posted its earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share (EPS) for the quarter. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. The firm had revenue of $35.77 million for the quarter. On average, analysts expect that Valneva SE Sponsored ADR will post -1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Valneva

Several hedge funds and other institutional investors have recently made changes to their positions in VALN. China Universal Asset Management Co. Ltd. bought a new position in Valneva in the 4th quarter worth approximately $44,000. JPMorgan Chase & Co. bought a new stake in Valneva during the 3rd quarter valued at $124,000. XTX Topco Ltd bought a new stake in Valneva during the 4th quarter valued at $94,000. Finally, Marex Group plc acquired a new position in Valneva during the 2nd quarter worth $64,000. 11.39% of the stock is currently owned by institutional investors and hedge funds.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.